{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T18:56:04Z","timestamp":1789757764819,"version":"4.0.1"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CPD"],"published-print":{"date-parts":[[2017,5,12]]},"DOI":"10.2174\/1381612823666170125160108","type":"journal-article","created":{"date-parts":[[2017,2,23]],"date-time":"2017-02-23T17:37:31Z","timestamp":1487871451000},"page":"1562-1570","source":"Crossref","is-referenced-by-count":17,"title":["Apolipoprotein(a) Antisense Oligonucleotides: A New Treatment Option for Lowering Elevated Lipoprotein(a)?"],"prefix":"10.2174","volume":"23","author":[{"given":"Julia","family":"Schreml","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna","family":"Gouni-Berthold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","container-title":["Current Pharmaceutical Design"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/149512","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,15]],"date-time":"2017-05-15T10:27:39Z","timestamp":1494844059000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/node\/149512\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,12]]},"references-count":0,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,5,12]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1381612823666170125160108","relation":{},"ISSN":["1381-6128"],"issn-type":[{"value":"1381-6128","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5,12]]}}}